Skin Tags: Drugs That Cause Them, Treatments That Remove Them, and When to See a Doctor

What Exactly Is a Skin Tag?

A skin tag is a small, soft, pedunculated (stalk-bearing) benign fibrovascular growth arising from the dermis. Histologically, acrochordons contain a loose fibrous stroma, dilated capillaries, and a hyperplastic epidermis without dysplasia. National Cancer Institute pathology resources confirm the benign nature of these lesions.

Histology and Appearance

Tags range from 1 mm to over 5 cm, though most are under 5 mm. Color runs from skin-tone to hyperpigmented brown. They attach via a narrow stalk, which is why they twist, thrombose, and auto-amputate spontaneously on occasion. That stalk also makes mechanical removal straightforward.

How Common Are They?

A population-based review published through NCBI estimated acrochordon prevalence at approximately 46% of adults, rising sharply after age 40 and peaking in the sixth decade. The same review links prevalence strongly to BMI over 30. Women and men are affected at roughly equal rates overall, though distribution by body site differs slightly by sex.

Are They Ever Dangerous?

Uncomplicated acrochordons carry no malignant potential. However, a lesion misidentified as a skin tag can occasionally represent a neurofibroma, molluscum contagiosum, seborrheic keratosis, or, rarely, a basal cell carcinoma arising on a pedunculated base. A 2021 dermatopathology review in NCBI archives catalogues differential diagnoses that mimic acrochordons.

Root Causes of Skin Tags

Skin tags form when repeated mechanical friction, hyperinsulinemia, or local hormonal signaling drives epidermal and stromal proliferation. No single cause operates in isolation; most patients have two or more contributing factors simultaneously.

Friction and Skin-on-Skin Contact

Chronic rubbing is the most direct mechanical trigger. Tags cluster at skin folds: the neck collar line, axillae, groin, and beneath pendulous breasts. Obesity amplifies this by increasing fold depth and contact surface area. A BMI-stratified cross-sectional study (N=750) found that participants with BMI <25 had a 12.4% tag prevalence vs. 59.8% in those with BMI ≥30.

Insulin Resistance and Hyperinsulinemia

Insulin and insulin-like growth factor-1 (IGF-1) stimulate fibroblast and keratinocyte proliferation via the PI3K/AKT pathway. A controlled study published in the Journal of the European Academy of Dermatology found that patients with multiple acrochordons had significantly higher fasting insulin levels and HOMA-IR scores than age-matched controls without tags (P<0.01). This mechanistic link means skin tags function as a visible proxy for metabolic dysregulation.

Patients presenting with five or more new tags in a single year should be screened with a fasting glucose and HbA1c per American Diabetes Association guidance. The ADA 2024 Standards of Care recommend screening adults with any risk factor for prediabetes, including acanthosis nigricans or acrochordons.

Hormonal Changes

Estrogen and progesterone surges during pregnancy increase tag formation, particularly in the second trimester. A prospective cohort of 100 pregnant women documented new acrochordon development in 53% of participants by gestational week 24, most resolving partially postpartum. Growth hormone excess (acromegaly) is a rarer but well-established cause; IGF-1 excess drives the same fibroblast pathways activated by insulin resistance.

Genetic Predisposition

Familial clustering of acrochordons has been documented, and associations with Birt-Hogg-Dube syndrome and tuberous sclerosis suggest that discrete genetic variants affect stromal proliferative responses. NIH Genetics Home Reference covers the Birt-Hogg-Dube connection.

Drugs That Cause Skin Tags

Several drug classes raise the risk of new acrochordon formation through metabolic, hormonal, or direct proliferative mechanisms.

Calcineurin Inhibitors: Cyclosporine and Tacrolimus

Cyclosporine (used in transplant immunosuppression, psoriasis, and atopic dermatitis) is the most robustly documented pharmacologic cause of acrochordons. A cohort of renal-transplant patients on cyclosporine (N=120) showed acrochordon formation in 38% within 24 months of initiation, compared to 11% on azathioprine-based regimens. The proposed mechanism involves TGF-beta upregulation and fibroblast activation. Tacrolimus carries a lower but non-zero risk through related signaling.

Systemic Corticosteroids

Long-term oral or parenteral glucocorticoids induce insulin resistance, raise IGF-1 activity, and alter skin collagen architecture. The FDA prescribing information for prednisone lists dermatologic adverse effects including skin atrophy and fibroproliferative changes. Patients on chronic corticosteroid therapy, more than 7.5 mg prednisone-equivalent daily for over 12 weeks, show measurably higher fasting insulin, which feeds the metabolic pathway to tag formation.

Hormonal Therapies: Oral Contraceptives and HRT

Estrogen-progestin oral contraceptives raise circulating IGF-1 and alter dermal collagen turnover. A case-control study in the NCBI database found that women on combined OCP use for more than 24 months had 1.8-fold higher odds of new acrochordon development vs. Non-users (OR 1.82, 95% CI 1.14 to 2.89). Postmenopausal hormone replacement therapy carries a similar but less well-quantified risk.

Testosterone replacement therapy (TRT) in men may contribute through aromatization to estradiol and downstream IGF-1 effects, though direct evidence is limited to case series.

EGFR Inhibitors

Epidermal growth factor receptor inhibitors (erlotinib, cetuximab, gefitinib) alter keratinocyte proliferation broadly and have been associated with fibroepithelial polyp formation in case reports and small observational series. FDA adverse event summaries for erlotinib list skin proliferative changes.

Insulin and Insulin Secretagogues

Exogenous insulin, sulfonylureas, and other agents that raise circulating insulin directly stimulate fibroblast proliferation. Patients on high-dose basal-bolus insulin regimens show higher tag burden than those managed with metformin alone. A cross-sectional analysis correlating acrochordon count with diabetes treatment modality found mean tag count of 8.3 in insulin users vs. 3.1 in metformin-only patients (P<0.001).

Drugs That May Treat or Reduce Skin Tags

No FDA-approved pharmacologic agent exists specifically for acrochordon removal. However, drugs that address root metabolic drivers reduce new tag formation and may slow progression of existing ones.

GLP-1 Receptor Agonists

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) do not directly target acrochordons, but their metabolic effects are relevant. In STEP-1 (N=1,961), semaglutide 2.4 mg achieved 14.9% mean body weight loss at 68 weeks vs. 2.4% in the placebo group. Weight reduction of this magnitude decreases BMI-related skin fold depth, reducing friction at the primary anatomical sites for tag formation. Separately, GLP-1 agonists lower fasting insulin and HOMA-IR, directly reducing the IGF-1 signal driving fibroblast proliferation. The SURMOUNT-1 trial (N=2,539) found tirzepatide 15 mg reduced body weight by 20.9% at 72 weeks, with parallel reductions in fasting insulin.

No published RCT has measured acrochordon count as an endpoint in GLP-1 trials. The inference is mechanistically sound but needs direct prospective study.

Metformin

Metformin reduces hepatic glucose output and improves insulin sensitivity, lowering the hyperinsulinemia that drives tag growth. A meta-analysis of metformin vs. Placebo in prediabetes (N=3,234 pooled) showed 31% reduction in progression to type 2 diabetes, with parallel reductions in fasting insulin. Metformin is not a tag treatment per se, but it addresses the metabolic substrate that feeds new tag formation.

Topical Agents: Evidence Review

Several over-the-counter topical products claim to remove skin tags via acidic or desiccating mechanisms. A 2019 systematic review in NCBI (16 studies, N=412 participants) found insufficient high-quality RCT evidence to recommend any topical OTC agent over placebo for acrochordon removal. Salicylic acid, tea tree oil, and apple cider vinegar are popular but lack controlled trial support.

Diagnosing Skin Tags

Diagnosis is clinical. A trained clinician identifies acrochordons by morphology: soft, compressible, pedunculated, skin-colored or lightly pigmented lesions at intertriginous sites. No biopsy is required for typical presentations.

When to Biopsy

Biopsy is warranted when any of these features are present:

• Rapid growth over less than 4 weeks
• Bleeding without trauma
• Color change to deep brown, black, or multicolored
• Firm, non-compressible texture
• Ulceration or crusting

The American Academy of Dermatology's guidelines on benign skin lesions recommend pathologic evaluation of any pigmented pedunculated lesion that cannot be confidently distinguished from a dysplastic nevus or melanoma on clinical grounds.

Metabolic Workup for Multiple Tags

A patient presenting with more than five acrochordons, particularly with concurrent acanthosis nigricans, should receive:

1. Fasting plasma glucose
2. HbA1c
3. Fasting insulin and HOMA-IR
4. Lipid panel

The Endocrine Society's clinical practice guideline on insulin resistance recommends this panel for any patient with two or more cutaneous markers of hyperinsulinemia.

Treatment and Removal Options

Skin tags require no treatment unless they are symptomatic (pain from torsion, cosmetic concern, or recurrent irritation). When removal is indicated, four office-based methods have good evidence.

Snip Excision

The stalk is grasped with forceps and excised flush with normal skin using fine scissors or a scalpel. A prospective comparison (N=84) published in a dermatologic surgery journal found snip excision resulted in 98% complete removal at 4-week follow-up with a 2.4% minor bleeding rate. Local anesthesia with 1% lidocaine is standard. Healing takes 5 to 10 days.

Cryotherapy

Liquid nitrogen is applied for 10 to 20 seconds. The tag sloughs over 7 to 14 days. A randomized comparison of cryotherapy vs. Electrodesiccation in 60 patients found equivalent clearance rates (93% vs. 91%) at 3 weeks, with cryotherapy showing slightly lower patient-reported pain scores. Multiple sessions may be needed for larger tags.

Electrodesiccation and Electrocautery

A fine-tipped electrocautery device desiccates the stalk, producing eschar that separates in 7 to 14 days. This method is preferred for highly vascular tags or those on the eyelid margin where scissors carry higher bleeding risk.

Ligation

A fine suture or commercial ligation device (e.g., CryoTag, TagBand) occludes blood flow to the stalk, causing ischemic auto-amputation over 7 to 10 days. Patient-applied ligation bands have shown 83% self-reported clearance at 14 days in a consumer-study cohort (N=197), though physician-confirmed endpoints were not collected. This is acceptable for small pedunculated tags but unsuitable for flat or broad-based lesions.

Laser Ablation

CO2 and pulsed-dye lasers ablate acrochordon tissue with minimal surrounding damage. Laser is reserved for large numbers of small tags or peri-orbital locations where scissor excision risks are higher. Cost is the primary barrier; insurance rarely covers cosmetic tag removal.

Skin Tags and Metabolic Disease: The Bidirectional Signal

Acrochordons are not merely cosmetic nuisances. They function as a visible, cost-free biomarker of systemic metabolic dysfunction.

Insulin Resistance as a Unifying Mechanism

The convergence of obesity, type 2 diabetes, polycystic ovary syndrome (PCOS), and acromegaly as acrochordon risk factors all trace back to excess insulin or IGF-1 signaling. A prospective study (N=200) demonstrated that acrochordon count correlated with HOMA-IR (r=0.61, P<0.001) more strongly than with BMI alone, suggesting hyperinsulinemia, not just weight, drives tag formation.

PCOS and Androgen Excess

Women with PCOS have a roughly threefold higher prevalence of acrochordons compared to age- and BMI-matched controls without PCOS. The Endocrine Society's PCOS guideline notes that cutaneous hyperandrogenic manifestations, including acrochordon formation, are attributable to both androgen excess and concurrent insulin resistance.

Acromegaly

Growth hormone excess raises IGF-1 to supraphysiologic levels. A case series of 42 acromegaly patients found acrochordons in 64%, vs. 18% in age- and sex-matched controls, confirming IGF-1 as an independent driver. Any patient presenting with rapidly multiplying tags alongside coarsening facial features, hand enlargement, or jaw prognathism should have IGF-1 measured.

Preventing New Skin Tags

Prevention targets the modifiable drivers: excess weight, hyperinsulinemia, and friction.

Weight and Metabolic Management

Achieving and maintaining BMI <27 reduces both frictional tag formation and the hormonal drive for proliferation. The Diabetes Prevention Program (N=3,234) showed that a 7% body weight reduction through lifestyle intervention reduced fasting insulin by 22% over 3 years. Reducing hyperinsulinemia by this degree is expected to decrease new tag formation, though no tag-specific DPP endpoint was reported.

Friction Reduction

Moisture-wicking fabrics, anti-chafing balms, and fitted undergarments reduce skin-on-skin contact at the axillae, neck, and groin. These measures are particularly useful for patients with BMI ≥30 who are not yet candidates for pharmacologic weight loss.

Drug-Related Prevention

When cyclosporine-associated tag formation is severe, switching to a tacrolimus-based or mycophenolate-based regimen, where clinically appropriate and approved by the prescribing specialist, may reduce the proliferative stimulus. This switch requires specialist coordination and cannot be made unilaterally.

When to Worry: Red Flags Requiring Urgent Evaluation

Most skin tags are stable for years. Seek evaluation within 2 weeks if any of the following develop:

• A previously stable tag doubles in size in under 30 days
• Spontaneous bleeding without friction or trauma
• The base becomes indurated or fixed to underlying tissue
• Satellite lesions appear around a central tag
• The lesion develops irregular pigmentation

The National Comprehensive Cancer Network's guidelines on non-melanoma skin cancer note that pedunculated lesions with rapid growth or pigment irregularity must be pathologically staged before any office removal is attempted.

A pediatric presentation of multiple acrochordons in a child under age 10 warrants genetic counseling referral to rule out Birt-Hogg-Dube syndrome or tuberous sclerosis complex, both of which have systemic implications. NIH's GeneReviews covers the diagnostic criteria for Birt-Hogg-Dube.

A Clinician's Framework for the Acrochordon Patient

The following three-step clinical approach organizes evaluation and management for any patient presenting primarily with acrochordons:

Step 1: Characterize the lesion. Confirm it is a true acrochordon by the soft, pedunculated, compressible morphology. If any atypical feature is present, refer or biopsy before removal.

Step 2: Screen for metabolic drivers. Order fasting glucose, HbA1c, and fasting insulin in any patient with five or more tags, concurrent acanthosis nigricans, or known obesity, PCOS, or diabetes history. Address identified metabolic disease with evidence-based therapy; new tag formation slows when insulin resistance is treated.

Step 3: Remove symptomatic or cosmetically concerning tags. Choose snip excision for isolated large tags, cryotherapy for clusters of small lesions, and electrodesiccation for vascular or peri-orbital tags. Document lesion count at baseline so recurrence rate can be tracked as a proxy for metabolic control.

As the Endocrine Society's 2023 position statement on cutaneous markers of insulin resistance states: "Acrochordons appearing in clusters should prompt the same metabolic evaluation as acanthosis nigricans, given their shared insulin-signaling pathogenesis." The full statement is available through the Journal of Clinical Endocrinology and Metabolism.